Six details:
1. Full-year 2020 U.S. revenue is expected to see year-over-year growth of about 30 percent.
2. New product sales represented about 75 percent of estimated U.S. revenue for the fourth quarter.
3. Growth was driven by the “rapid adoption” of Alphatec’s recently launched technologies and “strong pull-through from the SafeOp Neural InformatiX System,” the company said in a news release.
4. Alphatec Chairman and CEO Pat Miles said he was encouraged by the strong financial performance in 2020. “While we expect pandemic-related volume variability to persist into 2021, we will continue to drive adoption of novel procedures like [prone transpoas] while we work to close the EOS [imaging] transaction,” he said. “[Alphatec’s] best is yet to come.”
5. In December, the company entered into a renewed agreement to acquire EOS imaging in a $116.9 million all-cash transaction. The acquisition will strengthen Alphatec’s position in the spinal imaging sector.
6. Alphatec will report final fourth quarter and full-year 2020 financial results March 4.
More articles on devices:
Medtronic CEO predicts AI, machine learning as ‘the new frontier for medtech’ — 4 key quotes
40 orthopedic devices receiving FDA clearance in December
Stryker, Smith+Nephew seal 1st acquisitions of 2021: 7 device company notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
